Skip to main content
Erschienen in: Surgery Today 9/2013

01.09.2013 | Original Article

Clinical outcome of up-front surgery in patients with asymptomatic, incurable synchronous peritoneal carcinomatosis

verfasst von: Kenji Matsuda, Tsukasa Hotta, Katsunari Takifuji, Shozo Yokoyama, Yoshimasa Oku, Tadamichi Hashimoto, Hiromitsu Iwamoto, Hiroki Yamaue

Erschienen in: Surgery Today | Ausgabe 9/2013

Einloggen, um Zugang zu erhalten

Abstract

Purposes

The purpose of this study was to show the clinical features of up-front surgery of the primary tumor in asymptomatic patients with incurable colorectal PC.

Methods

Forty-six patients that were diagnosed between 1998 and 2007 with asymptomatic colorectal PC who could not be successfully cured by surgery were assessed retrospectively.

Results

A univariate analysis revealed the presence of liver metastases, without the use of oxaliplatin (OX)/irinotecan (IRI) and without a primary tumor resection to be poor prognostic factors for survival (p = 0.044, p = 0.030, p < 0.001, respectively). According to a multivariate analysis, no use of OX/IRI and no primary tumor resection, were found to be independent poor prognostic factors for survival (HR 2.57; p = 0.047, HR 6.62; p = 0.003, respectively). The median survival time of patients treated with and without OX/IRI was 18 and 7 months, respectively. The median survival time of patients with and without primary tumor resection was 10 and 2 months, respectively. The number of patients needing surgical intervention for intestinal obstruction after surgery significantly increased in patients treated with OX/IRI (p = 0.001).

Conclusion

Improvement of survival may be related to widespread use of modern systemic chemotherapy and primary tumor resection. However, an increased number of patients that needed surgery for an intestinal obstruction were observed, even after up-front surgery, when patients were treated with modern systemic chemotherapy.
Literatur
1.
Zurück zum Zitat Japanese Society for Cancer of the Colon and Rectum. Multi-Institutional Registry of Large Bowel Cancer in Japan. 2008;vol. 28. Cases treated in 1999. Japanese Society for Cancer of the Colon and Rectum. Multi-Institutional Registry of Large Bowel Cancer in Japan. 2008;vol. 28. Cases treated in 1999.
2.
Zurück zum Zitat Lemments V, Klaver Y, Verwaal V, Rutten HJ, Coebergh JWW, Hingh IH. Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: a population-based study. Int J Cancer. 2010;128:2717–25.CrossRef Lemments V, Klaver Y, Verwaal V, Rutten HJ, Coebergh JWW, Hingh IH. Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: a population-based study. Int J Cancer. 2010;128:2717–25.CrossRef
3.
Zurück zum Zitat Matsuda K, Hotta T, Takifuji K, Kobayashi Y, Tsuji T, Nagai Y, et al. Lymph node ratio is associated with the survival of colorectal cancer with peritoneal carcinomatosis. Am Surg. 2011;77(5):602–7.PubMed Matsuda K, Hotta T, Takifuji K, Kobayashi Y, Tsuji T, Nagai Y, et al. Lymph node ratio is associated with the survival of colorectal cancer with peritoneal carcinomatosis. Am Surg. 2011;77(5):602–7.PubMed
4.
Zurück zum Zitat Matsuda K, Hotta T, Takifuji K, Yamamoto M, Nasu T, Togo N, et al. Clinical impact of macroscopically complete resection of colorectal cancer with peritoneal carcinomatosis. Surgery. 2012;151:238–44.PubMedCrossRef Matsuda K, Hotta T, Takifuji K, Yamamoto M, Nasu T, Togo N, et al. Clinical impact of macroscopically complete resection of colorectal cancer with peritoneal carcinomatosis. Surgery. 2012;151:238–44.PubMedCrossRef
5.
Zurück zum Zitat Scheer M, Sloots C, Wilt J, Ruers J. Management of patients with asymptomatic colorectal cancer and synchronous irresectable metastases. Ann Oncol. 2008;19:1829–35.PubMedCrossRef Scheer M, Sloots C, Wilt J, Ruers J. Management of patients with asymptomatic colorectal cancer and synchronous irresectable metastases. Ann Oncol. 2008;19:1829–35.PubMedCrossRef
6.
Zurück zum Zitat Elias D, Gilly F, Boutitie F, Quenet F, Bereder JM, Mansvelt B, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol. 2010;28:63–8.PubMedCrossRef Elias D, Gilly F, Boutitie F, Quenet F, Bereder JM, Mansvelt B, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol. 2010;28:63–8.PubMedCrossRef
7.
Zurück zum Zitat Jayne DG, Fook S, Loi C, Seow-Choen F. Peritoneal carcinomatosis from colorectal cancer. Br J Surg. 2002;89:1545–50.PubMedCrossRef Jayne DG, Fook S, Loi C, Seow-Choen F. Peritoneal carcinomatosis from colorectal cancer. Br J Surg. 2002;89:1545–50.PubMedCrossRef
8.
Zurück zum Zitat Poultsides G, Servais E, Saltz L, Patil S, Kemeny N, Guillem J, et al. Outcomes of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J Clin Oncol. 2009;27:3379–84.PubMedCrossRef Poultsides G, Servais E, Saltz L, Patil S, Kemeny N, Guillem J, et al. Outcomes of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J Clin Oncol. 2009;27:3379–84.PubMedCrossRef
9.
Zurück zum Zitat Scoggins C, Meszoely I, Blanke C, Beauchamp D, Leach S. Nonoperative management of primary colorectal cancer in patients with stage IV disease. Ann Surg Oncol. 1999;6(7):651–7.PubMedCrossRef Scoggins C, Meszoely I, Blanke C, Beauchamp D, Leach S. Nonoperative management of primary colorectal cancer in patients with stage IV disease. Ann Surg Oncol. 1999;6(7):651–7.PubMedCrossRef
10.
Zurück zum Zitat Sarela A, Guthrie J, Seymour M, Ride E, Guillou P, O’Riordain D. Non-operative management of the primary tumour in patients with incurable stage IV colorectal cancer. Br J Surg. 2001;88:1352–6.PubMedCrossRef Sarela A, Guthrie J, Seymour M, Ride E, Guillou P, O’Riordain D. Non-operative management of the primary tumour in patients with incurable stage IV colorectal cancer. Br J Surg. 2001;88:1352–6.PubMedCrossRef
11.
Zurück zum Zitat Tebbut N, Norman A, Cunningham D, Hill M, Tait D, Oates J, et al. Intestinal complications after chemotherapy for patients with unresected primary colorectal cancer and synchronous metastases. Gut. 2003;52:568–73.CrossRef Tebbut N, Norman A, Cunningham D, Hill M, Tait D, Oates J, et al. Intestinal complications after chemotherapy for patients with unresected primary colorectal cancer and synchronous metastases. Gut. 2003;52:568–73.CrossRef
12.
Zurück zum Zitat Clements D, Rao P, Ramanathan D, Adams R, Maughan T, Davies M. Management of the asymptomatic primary in the palliative treatment of metastatic colorectal cancer. Colorectal Dis. 2009;11:845–8.PubMedCrossRef Clements D, Rao P, Ramanathan D, Adams R, Maughan T, Davies M. Management of the asymptomatic primary in the palliative treatment of metastatic colorectal cancer. Colorectal Dis. 2009;11:845–8.PubMedCrossRef
13.
Zurück zum Zitat Stelzner S, Hellmich G, Koch R, Ludwig K. Factors predicting survival in stage IV colorectal carcinoma patients after palliative treatment: a multivariate analysis. J Surg Oncol. 2005;89:211–7.PubMedCrossRef Stelzner S, Hellmich G, Koch R, Ludwig K. Factors predicting survival in stage IV colorectal carcinoma patients after palliative treatment: a multivariate analysis. J Surg Oncol. 2005;89:211–7.PubMedCrossRef
14.
Zurück zum Zitat Ruo L, Gougoutas C, Paty P, Guillem J, Cohen A, Wong D. Elective bowel resection for incurable stage IV colorectal cancer: prognostic variables for asymptomatic patients. J Am Coll Surg. 2003;196:722–8.PubMedCrossRef Ruo L, Gougoutas C, Paty P, Guillem J, Cohen A, Wong D. Elective bowel resection for incurable stage IV colorectal cancer: prognostic variables for asymptomatic patients. J Am Coll Surg. 2003;196:722–8.PubMedCrossRef
15.
Zurück zum Zitat Galizia G, Lieto E, Orditura M, Castellano P, Imperatore V, Pinto M, et al. First-line chemotherapy vs bowel tumor resection plus chemotherapy for patients with unresectable synchronous colorectal hepatic metastases. Arch Surg. 2008;143(4):352–8.PubMedCrossRef Galizia G, Lieto E, Orditura M, Castellano P, Imperatore V, Pinto M, et al. First-line chemotherapy vs bowel tumor resection plus chemotherapy for patients with unresectable synchronous colorectal hepatic metastases. Arch Surg. 2008;143(4):352–8.PubMedCrossRef
16.
Zurück zum Zitat Stillwell A, Buettner P, Ho Y-H. Meta-analysis of survival of patients with stage IV colorectal cancer managed with surgical resection versus chemotherapy alone. World J Surg. 2010;34:797–807.PubMedCrossRef Stillwell A, Buettner P, Ho Y-H. Meta-analysis of survival of patients with stage IV colorectal cancer managed with surgical resection versus chemotherapy alone. World J Surg. 2010;34:797–807.PubMedCrossRef
17.
Zurück zum Zitat Japanese Society for Cancer of the Colon and Rectum. Japanese classification of colorectal carcinoma, 2nd ed. Tokyo: Kanehara & Co., Ltd.; 2009. Japanese Society for Cancer of the Colon and Rectum. Japanese classification of colorectal carcinoma, 2nd ed. Tokyo: Kanehara & Co., Ltd.; 2009.
18.
Zurück zum Zitat McCahill LE, Yothers GA, Sharif S, Petrelli NJ, Lopa S, O’Connell MJ, et al. A Phase II trial of 5-fluorouracil, leucovorin and oxaliplatin (mFOLFOX6) chemotherapy plus bevacizumab (bev) for patients (pts) with unresectable stage IV colon cancer and a synchronous asymptomatic primary tumor: result of NSABP C-10. Proc Am Soc Clin Oncol. 2010;Abstr 3527. McCahill LE, Yothers GA, Sharif S, Petrelli NJ, Lopa S, O’Connell MJ, et al. A Phase II trial of 5-fluorouracil, leucovorin and oxaliplatin (mFOLFOX6) chemotherapy plus bevacizumab (bev) for patients (pts) with unresectable stage IV colon cancer and a synchronous asymptomatic primary tumor: result of NSABP C-10. Proc Am Soc Clin Oncol. 2010;Abstr 3527.
Metadaten
Titel
Clinical outcome of up-front surgery in patients with asymptomatic, incurable synchronous peritoneal carcinomatosis
verfasst von
Kenji Matsuda
Tsukasa Hotta
Katsunari Takifuji
Shozo Yokoyama
Yoshimasa Oku
Tadamichi Hashimoto
Hiromitsu Iwamoto
Hiroki Yamaue
Publikationsdatum
01.09.2013
Verlag
Springer Japan
Erschienen in
Surgery Today / Ausgabe 9/2013
Print ISSN: 0941-1291
Elektronische ISSN: 1436-2813
DOI
https://doi.org/10.1007/s00595-012-0348-9

Weitere Artikel der Ausgabe 9/2013

Surgery Today 9/2013 Zur Ausgabe

Leitlinien kompakt für die Allgemeinmedizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Facharzt-Training Allgemeinmedizin

Die ideale Vorbereitung zur anstehenden Prüfung mit den ersten 49 von 100 klinischen Fallbeispielen verschiedener Themenfelder

Mehr erfahren

Chronische Verstopfung: „Versuchen Sie es mit grünen Kiwis!“

22.05.2024 Obstipation Nachrichten

Bei chronischer Verstopfung wirken Kiwis offenbar besser als Flohsamenschalen. Das zeigen die Daten aus einer randomisierten Studie, die der Gastroenterologe Oliver Pech beim Praxis-Update vorstellte.

So häufig greift rheumatoide Arthritis auf Organe über

21.05.2024 Rheumatoide Arthritis Nachrichten

Im Verlauf von rheumatoider Arthritis entwickeln viele Patienten extraartikuläre Manifestationen. Schwedische Forscher haben sich mit der Inzidenz und den Risikofaktoren befasst.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Bei Herzinsuffizienz muss „Eisenmangel“ neu definiert werden

16.05.2024 Herzinsuffizienz Nachrichten

Bei chronischer Herzinsuffizienz macht es einem internationalen Expertenteam zufolge wenig Sinn, die Diagnose „Eisenmangel“ am Serumferritin festzumachen. Das Team schlägt vor, sich lieber an die Transferrinsättigung zu halten.

Update Allgemeinmedizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.